JRF 107
Alternative Names: JRF-107Latest Information Update: 22 Apr 2021
At a glance
- Originator Chengdu Jinrui Foundation Biotech
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-small cell lung cancer
Most Recent Events
- 22 Apr 2021 Discontinued - Preclinical for Non-small cell lung cancer in China (unspecified route) (Chengdu Jinrui Foundation Biotech pipeline, April 2021)
- 29 Jul 2020 Preclinical trials in Non-small cell lung cancer in China (unspecified route), prior to July 2020 (Chengdu Jinrui Foundation Biotech pipeline, July 2020)
- 29 Jul 2020 Chengdu Jinrui Foundation Biotech plans to submit an IND application for Non-small cell lung cancer, in 2021 (Chengdu Jinrui Foundation Biotech pipeline, July 2020)